Immutep (IMM): Lung May Jump Breast Cancer in Trial Queue
IMM reported positive headline data from its expanded TACTI-002 part A trial in first line (1L) non small cell lung cancer (NSCLC) at ASCO last week.
414 Views
Immutep Limited: Leading Not Lagging in Immuno-Oncology Development
Immutep Limited Leading not lagging in immuno-oncology development Immutep Limited (ASX:IMM) is a biotechnology company that is a leader in the...
1.1k Views
Immutep - A big year ahead for efti
We expect Immutep to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod alpha...
56 Views
Immutep - A big year ahead for efti
We expect Immutep to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod alpha...
44 Views
Immutep - A second big pharma collaboration for efti
Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator...
53 Views